In our latest paper published in the International Journal of Hyperthermia we report on the treatment outcomes of 44 patients with stage IV metastatic non-small cell lung cancer (NSCLC) treated at Chemothermia and diagnosed between March 2010 and June 2015.
In this group of patients who had a significantly higher percentage of brain metastases and worse performance status than in other NSCLC trials using the same drug combination we report an overall survival time of 42.9 months compared to 6.3-11.3 months in other studies.
The article can be downloaded here:
Feasibility study of metabolically supported
chemotherapy with weekly carboplatin/paclitaxel
combined with ketogenic diet, hyperthermia and
hyperbaric oxygen therapy in metastatic nonsmall
cell lung cancer